Grab Source And Key Details Here: Company Presentation.
-----
And as mentioned above, NBY has several potential catalysts that could help provide a breakout spark. Check these out:
No. 1: Explosive Volatility Potential Based On NBY's Float Is Must-Know Material.
According to the Yahoo Finance website, NBY has a low float.
The website reports this profile to have approximately 6.24Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive company early in 2024 provide a breakout spark for NBY?
No. 2: An Analyst Targets Could Suggest As Much As 1,800% Potential Upside.
Edward Woo, an analyst at Ascendiant Capital Markets, has tagged NBY with a $3.50 price target.
From Monday's opening valuation, that provides NBY with an incredible upside potential of 1,800+%.
Here's some key highlights from his report:
- Avenova products sales: Avenova product sales were $2.4Mn. The company also had $0.1Mn of NeutroPhase and PhaseOne wound careproduct sales.
- DERMAdoctor contribution: DERMAdoctor sales were $0.8Mn.
- DERMAdoctor: In September 2021, NovaBay announced the acquisition ofprivately held DERMAdoctor for ~$12Mn (in cash). DERMAdoctor produce sand sells more than 30 products under lines that include Ain’t Misbehavin’, Calm Cool + Corrected, Kakadu C, KP Duty, and Wrinkle Revenge. Its product sare designed to address acne, aging skin, dark spots, dry skin, eczema, and many other skin conditions. DERMAdoctor sells its products through major retailers such as Macy’s, QVC, Costco, digital beauty retailers such as SkinStoreand Amazon, as well as its own website. DERMAdoctor also has a large and growing network of international distributors and retailers. DERMAdoctor’s management has joined the NovaBay management team.
- DERMAdoctor new focus: The company is now shifting its strategy in its skincare segment away from new product development to focus more on driving sales of top-selling products through its most efficient sales channels. As part of this, Dr. Jeff Kunin and Dr. Audrey Kunin (founders of DERMAdoctor) will retire in November 2023.
- Management long term positive: NovaBay is making good progress to market its Avenova product to the 41 million Americans ($600Mn market opp.) who suffer from blepharitis and related eye symptoms. In addition, the acquisition of DERMAdoctor allows strong growth and synergy opp's in the global market for cosmetic skincare products. NovaBay plans to launch a broad range of complementary eye and skin care products. The company also plans to leverage operational synergies and sales/distribution relationships.
-----
No. 3: Oversold Technicals Indicators Point Towards A Potential Bounce/Reversal Scenario Brewing.
Rewind to 12:00PM EST Monday. Barchart was reporting multiple oversold technical indicators for NBY.
These technicals could be signaling a healthy reversal could be approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to:
- 9-Day Relative Strength Index: 24.63%
- 14-Day Relative Strength Index: 26.06%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 14.02%
- 14-Day Williams %R: 85.98%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
No. 4: NBY's Avenova Allograft Officially Launches (To Take On $400+Mn Market).
NovaBay Pharmaceuticals, Inc. has officially launched Avenova Allograft, a prescription product designed for eyecare professionals in the U.S. through its physician-dispensed channel.
Manufactured using BioStem Technologies, Inc.'s proprietary process, Avenova Allograft serves as a protective covering during the repair of ocular surfaces.
The commercial release follows a prior agreement granting NovaBay the right to market BioStem Technologies' Amniotic Tissue Allograft under the Avenova brand.
Positioned to compete in the global ophthalmology amniotic membrane market, valued at $403.6Mn in 2022 and expected to grow at a rate of 9.8% annually from 2023 to 2030, Avenova Allograft represents NovaBay's strategic entry into this expanding market.
Justin Hall, CEO and General Counsel of NovaBay shared: "Avenova Allograft is a valuable addition to our high-quality, differentiated eyecare franchise and allows us to provide another solution for the professionals who specialize in treating eye conditions. We have fostered strong relationships with eyecare professionals nationwide including thousands of optometrists and ophthalmologists who recommend, prescribe, and sell Avenova-branded products every day. Sales in our physician-dispensed channel continue to grow, providing us with a terrific platform to launch this innovative product."
-----
4 Pressing Potential Breakout Catalysts - NBY's Recap
No. 1: Explosive Volatility Potential Based On NBY's Float Is Must-Know Material.
No. 2: An Analyst Targets Could Suggest As Much As 1,800% Potential Upside.
No. 3: Oversold Technicals Indicators Point Towards A Potential Bounce/Reversal Scenario Brewing.
No. 4: NBY's Avenova Allograft Officially Launches (To Take On $400+Mn Market).
-----
Coverage is officially initiated on NovaBay Pharmaceuticals, Inc. (NBY).
When updates pop up moving forward, I'll get them out to you as quickly as possible. Talk again soon.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
